Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC
Conditions: Breast Cancer; HER2-positive Breast Cancer Interventions: Drug: Albumin paclitaxel+trastuzumab+pyrrolitinib; Drug: Docetaxel+Carboplatin+trastuzumab+Parstuzumab Sponsor: Henan Cancer Hospital Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 26, 2023 Category: Research Source Type: clinical trials
Trastuzumab Deruxtecan (T-DXd): Tailoring Treatment and Companion Diagnostics (CDx) by Liquid Biopsy
Condition: Metastatic Breast Cancer Intervention: Diagnostic Test: HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and objectively assess HER2 status at recruitment Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 26, 2023 Category: Research Source Type: clinical trials
Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC
Conditions: Breast Cancer; HER2-positive Breast Cancer Interventions: Drug: Albumin paclitaxel+trastuzumab+pyrrolitinib; Drug: Docetaxel+Carboplatin+trastuzumab+Parstuzumab Sponsor: Henan Cancer Hospital Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 26, 2023 Category: Research Source Type: clinical trials
Trastuzumab Deruxtecan (T-DXd): Tailoring Treatment and Companion Diagnostics (CDx) by Liquid Biopsy
Condition: Metastatic Breast Cancer Intervention: Diagnostic Test: HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and objectively assess HER2 status at recruitment Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 26, 2023 Category: Research Source Type: clinical trials
Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC
Conditions: Breast Cancer; HER2-positive Breast Cancer Interventions: Drug: Albumin paclitaxel+trastuzumab+pyrrolitinib; Drug: Docetaxel+Carboplatin+trastuzumab+Parstuzumab Sponsor: Henan Cancer Hospital Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 26, 2023 Category: Research Source Type: clinical trials
Trastuzumab Deruxtecan (T-DXd): Tailoring Treatment and Companion Diagnostics (CDx) by Liquid Biopsy
Condition: Metastatic Breast Cancer Intervention: Diagnostic Test: HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and objectively assess HER2 status at recruitment Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 26, 2023 Category: Research Source Type: clinical trials
Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC
Conditions: Breast Cancer; HER2-positive Breast Cancer Interventions: Drug: Albumin paclitaxel+trastuzumab+pyrrolitinib; Drug: Docetaxel+Carboplatin+trastuzumab+Parstuzumab Sponsor: Henan Cancer Hospital Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 26, 2023 Category: Research Source Type: clinical trials
Trastuzumab Deruxtecan (T-DXd): Tailoring Treatment and Companion Diagnostics (CDx) by Liquid Biopsy
Condition: Metastatic Breast Cancer Intervention: Diagnostic Test: HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and objectively assess HER2 status at recruitment Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 26, 2023 Category: Research Source Type: clinical trials
Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC
Conditions: Breast Cancer; HER2-positive Breast Cancer Interventions: Drug: Albumin paclitaxel+trastuzumab+pyrrolitinib; Drug: Docetaxel+Carboplatin+trastuzumab+Parstuzumab Sponsor: Henan Cancer Hospital Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 26, 2023 Category: Research Source Type: clinical trials
Trastuzumab Deruxtecan (T-DXd): Tailoring Treatment and Companion Diagnostics (CDx) by Liquid Biopsy
Condition: Metastatic Breast Cancer Intervention: Diagnostic Test: HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and objectively assess HER2 status at recruitment Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 26, 2023 Category: Research Source Type: clinical trials
Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC
Conditions: Breast Cancer; HER2-positive Breast Cancer Interventions: Drug: Albumin paclitaxel+trastuzumab+pyrrolitinib; Drug: Docetaxel+Carboplatin+trastuzumab+Parstuzumab Sponsor: Henan Cancer Hospital Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 26, 2023 Category: Research Source Type: clinical trials
Trastuzumab Deruxtecan (T-DXd): Tailoring Treatment and Companion Diagnostics (CDx) by Liquid Biopsy
Condition: Metastatic Breast Cancer Intervention: Diagnostic Test: HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and objectively assess HER2 status at recruitment Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 26, 2023 Category: Research Source Type: clinical trials
Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC
Conditions: Breast Cancer; HER2-positive Breast Cancer Interventions: Drug: Albumin paclitaxel+trastuzumab+pyrrolitinib; Drug: Docetaxel+Carboplatin+trastuzumab+Parstuzumab Sponsor: Henan Cancer Hospital Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 26, 2023 Category: Research Source Type: clinical trials
Trastuzumab Deruxtecan (T-DXd): Tailoring Treatment and Companion Diagnostics (CDx) by Liquid Biopsy
Condition: Metastatic Breast Cancer Intervention: Diagnostic Test: HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and objectively assess HER2 status at recruitment Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 26, 2023 Category: Research Source Type: clinical trials
